TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications
CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval. To view the full press release, visit https://ibn.fm/OENah About…